Johnson & Johnson Completes Acquisition of Shockwave Medical
Strengthens Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention
Creates Greater Opportunity to Transform the Treatment Landscape for Cardiovascular Disease
This transaction further extends Johnson & Johnson MedTech’s leadership in cardiovascular intervention. Shockwave offers the first and only commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD) and complements Johnson & Johnson’s leading positions in heart recovery (Abiomed) and electrophysiology (
Shockwave is ultimately expected to become Johnson & Johnson MedTech’s thirteenth priority platform, as defined by annual sales of at least
In connection with the completion of the transaction, Shockwave’s common stock ceased trading on NASDAQ.
About
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and
Cautions Concerning Forward-Looking Statements
-
This communication contains “forward-looking statements” regarding the acquisition of Shockwave by
Johnson & Johnson . - The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.
-
If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of
Johnson & Johnson or Shockwave. Risks and uncertainties include, but are not limited to: challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; economic conditions, including currency exchange and interest rate fluctuations; the risks associated with global operations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including tax laws and global health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care services and products; and trends toward health care cost containment. -
In addition, there will be risks and uncertainties related to the ability of the
Johnson & Johnson family of companies to successfully integrate the programs, products, technologies and employees/operations and clinical work of Shockwave. A further list and description of these risks, uncertainties and other factors and the general risks associated with the respective businesses ofJohnson & Johnson and Shockwave can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year endedDecember 31, 2023 , filed with theSEC onFebruary 16, 2024 , including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in Johnson & Johnson’s most recently filed Quarterly Report on Form 10-Q for the quarterly period endedMarch 31, 2024 , filed with theSEC onMay 1, 2024 , in Johnson & Johnson’s subsequent filings with theSEC and in Shockwave’s Annual Report on Form 10-K for the fiscal year endedDecember 31, 2023 , filed with theSEC onFebruary 26, 2024 , including in the sections captioned “Special Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in Shockwave’s Quarterly Report on Form 10-Q for the quarterly period endedMarch 31, 2024 , filed with theSEC onMay 6, 2024 , and in Shockwave’s subsequent filings with theSEC . Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com, https://shockwavemedical.com/ or on request fromJohnson & Johnson or Shockwave. NeitherJohnson & Johnson nor Shockwave undertakes to update any forward-looking statement as a result of new information or future events or developments, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530938029/en/
Media Contact:
media-relations@its.jnj.com
Investor Contact:
investor-relations@its.jnj.com
Source: